Safety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 800 participants.
Also called NCT07414342
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 800 participants
- Sponsor
- Beijing Balance Medical Technology Co., Ltd
- Registry
-
NCT07414342
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07414342. Allocation not applicable; no masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2027-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis
- Condition
- Severe Aortic Stenosis
- Intervention (Device)
- RENATUS® TAVR (transcatheter aortic valve replacement)
- Lead sponsor
- Beijing Balance Medical Technology Co., Ltd
Record details
- Record id
cardio:ct-nct07414342- Content hash
7a3c51bc5a6e020839587f7b97a7e3dff926f30a35644aec8b3c0a40c1501ce1